PA-22-168: AHRQ Administrative Supplements for Grants in Health Services Research
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for Health Care Research and Quality notices from 2022.
Agency for Health Care Research and Quality offered grants to colleges and universities. Applications closed on March 25, 2026.
From the official notice on Grants.gov, last changed March 25, 2026. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | April 7, 2022 |
|---|---|
| Deadline | March 25, 2026 |
| Archived by Grants.gov | March 26, 2026 |
Who can apply
This opportunity was open to colleges and universities.
- Public and State controlled institutions of higher education
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. see the funding announcement for eligibility details
Is this a realistic fit?
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to inform Agency for Healthcare Research and Quality (AHRQ) grantees holding active AHRQ awards that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the competing application was submitted. Although requests for administrative supplements may be submitted to this NOFO, there is no guarantee that funds will be available from the awarding agency for any specific grant. Applicants are encouraged to discuss potential requests with the assigned AHRQ staff contacts for their project prior to submission.
Who has won Research on Healthcare Costs, Quality and Outcomes grants before
From fiscal 2021 to 2025, Research on Healthcare Costs, Quality and Outcomes (93.226) awarded $686 million across 791 grant awards, an average of $867,535 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 45 | $46.0 million |
| The Johns Hopkins University | Maryland | 25 | $23.6 million |
| Brigham & Womens Hospital Inc | Massachusetts | 16 | $22.2 million |
| The Regents of the University of California, San Francisco | California | 22 | $19.4 million |
| The Regents of the University of Colorado | Colorado | 23 | $18.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PA-22-168 still open?
No. It closed on March 25, 2026.
Who can apply for AHRQ Administrative Supplements for Grants in Health Services Research?
Agency for Health Care Research and Quality accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for AHRQ Administrative Supplements for Grants in Health Services Research?
Closed March 25, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Research on Healthcare Costs, Quality and Outcomes grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, Brigham & Womens Hospital Inc. The program made 791 awards worth $686 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)